Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Total	As Previously Reported	Retroactive Application of the Recapitalization Due to the Business Combination	Common Stock [Member]	Common Stock [Member] Retroactive Application of the Recapitalization Due to the Business Combination	Additional Paid-in Capital	Additional Paid-in Capital As Previously Reported	Additional Paid-in Capital Retroactive Application of the Recapitalization Due to the Business Combination	Accumulated Deficit	Accumulated Deficit As Previously Reported	Old Gemini Common Stock [Member] As Previously Reported	Old Gemini Common Stock [Member] Retroactive Application of the Recapitalization Due to the Business Combination	Series A Convertible Preferred Stock As Previously Reported	Series A Convertible Preferred Stock Retroactive Application of the Recapitalization Due to the Business Combination	Series B Convertible Preferred Stock As Previously Reported	Series B Convertible Preferred Stock Retroactive Application of the Recapitalization Due to the Business Combination
Balance at Dec. 31, 2020	$ (21,861,000)	$ (102,310,000)	$ 80,449,000	$ 2,000	$ 2,000	$ 90,958,000	$ 10,504,000	$ 80,454,000	$ (112,821,000)	$ (112,821,000)	$ 7,000	$ (7,000)
Balance (in Shares) at Dec. 31, 2020													39,722,088	(39,722,088)	24,790,938	(24,790,938)
Balance at Dec. 31, 2020													$ 47,113,000	$ (47,113,000)	$ 33,336,000	$ (33,336,000)
Balance (in Shares) at Dec. 31, 2020				15,565,380	15,565,380						6,900,493	(6,900,493)
Issuance of common stock upon Business Combination, net of issuance costs (Note 3)	195,882,000			$ 2,000		195,880,000
Issuance of common stock upon Business Combination, net of issuance costs (in Shares)				25,041,150
Conversion of promissory notes (Note 3)	14,515,000					14,515,000
Conversion of promissory notes (in Shares)				2,341,316
Issuance of common stock upon exercise of warrants (Note 3)	76,000					76,000
Issuance of common stock upon exercise of warrants (in Shares)				15,257
Issuance of common stock upon exercise of stock options	4,000					4,000
Issuance of common stock upon exercise of stock options (in Shares)				3,480
Vesting of restricted common stock (in Shares)				35,561
Stock-based compensation expense	1,593,000					1,593
Net loss	(19,048,000)								(19,048)
Balance at Mar. 31, 2021	171,161,000			$ 4		303,026			(131,869)
Balance (in Shares) at Mar. 31, 2021				43,002,144
Balance at Dec. 31, 2021	124,841,000	$ (124,841,000)		$ 4,000		309,527,000			(184,690,000)
Balance (in Shares) at Dec. 31, 2021				43,208,159
Issuance of common stock upon exercise of stock options	25,000					25,000
Issuance of common stock upon exercise of stock options (in Shares)				19,000
Stock-based compensation expense	1,976,000					1,976,000
Net loss	(15,231,000)								(15,231,000)
Balance at Mar. 31, 2022	$ 111,611,000			$ 4,000		$ 311,528			$ (199,921)
Balance (in Shares) at Mar. 31, 2022				43,227,159